Abt-C6-2017- A Randomized Phase I/II Open Label Study To Assess The Efficacy And Safety Of Abtl0812 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer At First Line Therapy
Posted Date: May 6, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The main purpose of this study is to evaluate ABTL0812 in combination with gemcitabine and nab-paclitaxel as first line therapy in advanced pancreatic cancer. This will be evaluated by determining the number of emergent adverse events.
Criteria:
Patient Has Histologically Or Cytologically Confirmed Metastatic Adenocarcinoma Of The Pancreas, One Or More Metastatic Tumors, Ecog 0-1, Adequate Organ Function Per Protocol, Life Expectancy = 12 Weeks, No Symptomatic Brain Metastases, No Evidence Of Pre-Existing Uncontrolled Hypertension, No Hepatitis B Or C, No Medical Conditions That In The Opinion Of The Investigator May Interfere With The Planned Treatment, Affect Patient Compliance Or Place The Patient At High Risk From Treatment-Related Complications.
Keywords:
Pancreatic Cancer, Advanced
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com